Ceesay Abraham 4
4 · Rapport Therapeutics, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics (RAPP) CEO Ceesay Sells 10,916 Shares
What Happened
- Ceesay Abraham, CEO of Rapport Therapeutics (RAPP), sold a total of 10,916 shares in open-market transactions on February 18, 2026, generating approximately $320,373 in proceeds. The filing reports four sale lots with reported (weighted-average) prices of $29.05, $29.80, $29.04 and $29.80 per share, respectively.
Key Details
- Transaction date: February 18, 2026; Form 4 filed February 19, 2026 (timely).
- Lots sold: 3,552; 2,281; 2,983; and 2,100 shares (total 10,916).
- Reported proceeds (sum): ~$320,373.
- Reported per-lot prices (weighted averages): $29.05, $29.80, $29.04, $29.80.
- Actual sale prices occurred across multiple executions — ranges reported roughly between $28.51 and $30.09 across the lots; the filer offers to provide exact per-price counts on request.
- Footnote: Transactions were effected under pre-established Rule 10b5-1 trading plans adopted December 12, 2024.
- Ownership after the trades is not specified in the provided data; the filing includes trust-related disclaimers that some shares are held by family irrevocable trusts (the filer disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest).
Context
- These were sales (S) executed under a 10b5-1 plan, which are pre-set trading plans that allow insiders to sell shares at predetermined times and are generally viewed as routine rather than a direct signal of near-term insider sentiment. No options exercise, gifts, or tax-withholding events are reported in the supplied transactions.
Insider Transaction Report
Form 4
Ceesay Abraham
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-18$29.05/sh−3,552$103,191→ 558,528 total - Sale
Common Stock
[F1][F3]2026-02-18$29.80/sh−2,281$67,970→ 556,247 total - Sale
Common Stock
[F1][F4][F6]2026-02-18$29.04/sh−2,983$86,639→ 22,829 total(indirect: By Trust) - Sale
Common Stock
[F1][F5][F6]2026-02-18$29.80/sh−2,100$62,573→ 20,729 total(indirect: By Trust)
Holdings
- 81,729(indirect: By Trust)
Common Stock
[F7]
Footnotes (7)
- [F1]These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F6]Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F7]Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/ Troy Ignelzi, Attorney-in-Fact|2026-02-19